Targeting N-myc in childhood brain tumors for better treatments
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications
This study is looking at how a protein called N-myc plays a role in the growth of medulloblastoma, a common brain tumor in kids, to find new ways to treat this cancer and help improve the lives of young patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10890126 on NIH RePORTER |
What this research studies
This research investigates how the N-myc transcription factor contributes to the development of medulloblastoma, the most common malignant brain tumor in children. By understanding how N-myc interacts with the cellular machinery that produces proteins, the researchers aim to identify new therapeutic strategies that could specifically target this factor. The study employs advanced techniques like ribosome profiling to analyze the translation of specific mRNAs that are crucial for tumor growth. Ultimately, the goal is to develop targeted therapies that can improve outcomes for children affected by this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with N-myc amplified medulloblastoma.
Not a fit: Patients with other types of brain tumors or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with N-myc driven medulloblastoma, potentially improving survival rates and reducing long-term disabilities.
How similar studies have performed: Other research has shown promising results in targeting molecular pathways in cancers, suggesting that this approach could be effective, although the specific targeting of N-myc in medulloblastoma is a novel area of investigation.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Weiss, William a — University of California, San Francisco
- Study coordinator: Weiss, William a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.